The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst
: Great. Maybe we can start off with sparsentan? You've filed for approval in IgAN. And could you walk us maybe through the scenarios for the
ultimate approval there and the upcoming acceptance that you expect here in the coming weeks?
Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst
: Great. Yes, that leads into the next question, which is, your plans for the commercial launch of sparsentan. Where are you at with that process? And
what needs...
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MAY 10, 2022 / 11:00PM, TVTX.OQ - Travere Therapeutics Inc at Bank of America Healthcare Conference
Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst
: Great. Now, how are you looking at this initial market in IgAN relative to some of the more very rare, ultra-rare indications that you're in currently?
Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst
: Great. That's helpful. Now, when it comes to reaching out to these physicians, what's your strategy there for both choosing the correct ones that
are most likely use sparsentan? Maybe what education is necessary to get them over, maybe some of that conservatism you mentioned? Just how
are you thinking about that?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MAY 10, 2022 / 11:00PM, TVTX.OQ - Travere Therapeutics Inc at Bank of America Healthcare Conference
Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst
: So how are we thinking about the -- or how should we be thinking about the EU opportunity and your collaboration with your partner in terms of
both the market opportunity, as well as how to get the best launch in your partnership there?
Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst
: Great. Maybe we'll move on to FSGS a little bit. Could you walk us through the time lines there as far as your approval? And how that preparation
for that commercial launch kind of intersects with that of IgAN?
Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst
: Great. Now, I think you've said you will not likely disclose the eGFR data publicly at that time. But is there any sense of what you can give us of what
would be supportive as far as eGFR 2-year application?
Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst
: Okay. What's your sense of demand within the community of FSGS patients and their physicians for a new treatment like sparsentan?
Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst
: Okay. Great. Now, is this -- would this be a similar market in your view with IgAN where you might be looking at certain subpopulations within? Or
would you expect the sparsentan's mechanism be more likely to apply broadly across the spectrum of severity within FSGS?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MAY 10, 2022 / 11:00PM, TVTX.OQ - Travere Therapeutics Inc at Bank of America Healthcare Conference
Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst
: Understood. Now, how does that kind of translate into your expectations for a market uptake maybe relative to IgAN? Is there maybe any differences
between the 2 and your expectations for how fast the launch could go? How fast patients will get on treatment? Or even the -- how well diagnosed
they are?
Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst
: Okay. That makes sense. And then how should people be thinking about pricing? There's obviously -- you've demonstrated that patients benefit
from the medication. But within the context of potentially combos and maybe patients are already on several drugs, how does that impact your
decision on how to price sparsentan?
Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst
: Great. Let's move on to the pegtibatinase program. Maybe if you could give your thoughts on what led you to acquire this program? And where
it fits in with your pipeline? And what you think the opportunity is there?
Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst
: Great. Now, what would a pivotal trial in this indication look like? I'm just trying to get a sense of size, time lines, that sort of thing.
Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst
: Great. Now, let's maybe discuss the base business a little bit. You have several approved products. And some are starting to face some more generic
competition. So how should we be thinking about the trend there and the potential durability of those franchisees?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MAY 10, 2022 / 11:00PM, TVTX.OQ - Travere Therapeutics Inc at Bank of America Healthcare Conference
Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst
: Great. Okay. One last question from us is, what are your plans as far as business development activity, in-licensing new products, maybe even life
cycle management for sparsentan down the road? Are you seeing more attractive deals in the current environment? Or is this more the time to
maybe conserve capital and just focus on execution of what you're doing now?
Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst
: Great. Well, with that, I think our time is about up. So, Eric, I'd like to thank you for joining us today, and thank all of you for joining us as well.
| 
